The research proposed by the University of Texas SPORE in Prostate Cancer encompasses a broad range of activities, including studies in cell lines, animal models, and clinical trials. These studies will generate many different types of data, including clinical, epidemiological, biochemical, and immunohistochemical, pharmacokinetics, genotype and immunologic data. The Biostatistics and Bioinformatics Core provides comprehensive biostatistics and bioinformatics expertise to ensure the statistical integrity and to optimize data analysis of the studies by the SPORE. It will incorporate sound experimental design principles within each project that will enhance interpretability of study results, will carry out data analyses using appropriate statistical methodology, and will contribute to interpretation of results through written reports and frequent interaction with project investigators. Members of the Core participate in monthly SPORE meeting with all project investigators, ensuring that proper consideration is taken of biostatistics and data management issues during all phases of SPORE experiments. The Biostatistics and Bioinformatics Core will further provide an integrated data management system to facilitate communication among all projects and cores, which will be customized to meet the needs of the Prostate SPORE. This process includes prospective data collection, data quality control, data security, and patient confidentiality. Thus, from inception to reporting, translational experiments will benefit from SPORE resources that will be used to augment existing M.D. Anderson Cancer Center biostatistics resources.
The specific aims of the Biostatistics and Bioinformatics Core are:
Aim 1. To provide valid statistical designs of laboratory research, clinical trials and translational experiments arising from the ongoing research of the SPORE.
Aim 2. To develop and conduct the innovative statistical modeling, simulations, and data analyses needed by the Projects, Developmental Projects, and other Cores to achieve their specific aims.
Aim 3. To ensure that the results of all Projects are based on well-designed experiments, appropriately interpreted, and to assist in the preparation of manuscripts describing these results.
Aim 4. To develop integrated computational libraries and tools for producing documented, reproducible statistical analyses, and to make these tools available to all SPORE participants.

Public Health Relevance

Core B personnel will collaborate with every one of the five proposed projects, will interact with the other cores and also will expect to interact with all funded development awards, and thus this core is crucially important to the SPORE. Areas where biostatistical and bioinformatics expertise are indispensable are in clinical trial, experimental design, and data analysis with integrated multi-platform data. It will be apparent from this proposal that Core personnel play a significant role in designing the proposed experiments/trials and in planning the data analysis in conjunction with an integrated data management system.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA140388-04
Application #
8380597
Study Section
Special Emphasis Panel (ZCA1-RPRB-7)
Project Start
Project End
Budget Start
2012-09-01
Budget End
2013-08-31
Support Year
4
Fiscal Year
2012
Total Cost
$243,868
Indirect Cost
$84,501
Name
University of Texas MD Anderson Cancer Center
Department
Type
DUNS #
800772139
City
Houston
State
TX
Country
United States
Zip Code
77030
Luo, Yong; Azad, Abul Kalam; Karanika, Styliani et al. (2017) Enzalutamide and CXCR7 inhibitor Combination Treatment Suppresses Cell Growth and Angiogenic Signaling in Castration-Resistant Prostate Cancer Models. Int J Cancer :
Lin, Song-Chang; Lee, Yu-Chen; Yu, Guoyu et al. (2017) Endothelial-to-Osteoblast Conversion Generates Osteoblastic Metastasis of Prostate Cancer. Dev Cell 41:467-480.e3
Gao, Jianjun; Ward, John F; Pettaway, Curtis A et al. (2017) VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer. Nat Med 23:551-555
Yu, Kai-Jie; Li, Jeffrey K; Lee, Yu-Chen et al. (2017) Cabozantinib-induced osteoblast secretome promotes survival and migration of metastatic prostate cancer cells in bone. Oncotarget 8:74987-75006
Tu, Huakang; Gu, Jian; Meng, Qing H et al. (2017) Low serum testosterone is associated with tumor aggressiveness and poor prognosis in prostate cancer. Oncol Lett 13:1949-1957
Gökce, Mehmet I; Wang, Xuemei; Frost, Jacqueline et al. (2017) Informed decision making before prostate-specific antigen screening: Initial results using the American Cancer Society (ACS) Decision Aid (DA) among medically underserved men. Cancer 123:583-591
Karanika, Styliani; Karantanos, Theodoros; Li, Likun et al. (2017) Targeting DNA Damage Response in Prostate Cancer by Inhibiting Androgen Receptor-CDC6-ATR-Chk1 Signaling. Cell Rep 18:1970-1981
Saha, Achinto; Blando, Jorge; Fernandez, Irina et al. (2016) Linneg Sca-1high CD49fhigh prostate cancer cells derived from the Hi-Myc mouse model are tumor-initiating cells with basal-epithelial characteristics and differentiation potential in vitro and in vivo. Oncotarget 7:25194-207
Fong, Eliza L S; Wan, Xinhai; Yang, Jun et al. (2016) A 3D in vitro model of patient-derived prostate cancer xenograft for controlled interrogation of in vivo tumor-stromal interactions. Biomaterials 77:164-72
Subudhi, Sumit K; Aparicio, Ana; Gao, Jianjun et al. (2016) Clonal expansion of CD8 T cells in the systemic circulation precedes development of ipilimumab-induced toxicities. Proc Natl Acad Sci U S A 113:11919-11924

Showing the most recent 10 out of 198 publications